Guenin E - Search Results

1

Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.

Tanghetti EA, Werschler WP, Lain E, Guenin E, Harris S, Loncaric A, Pillai R. Tanghetti EA, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Mar 1;19(3):272-279. doi: 10.36849/JDD.2020.4869. J Drugs Dermatol. 2020. PMID: 32549090

2

Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.

Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R. Tyring SK, et al. Among authors: guenin e. J Drugs Dermatol. 2018 Oct 1;17(10):1084-1091. J Drugs Dermatol. 2018. PMID: 30365589 Clinical Trial.

3

Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.

Eichenfield LF, Sugarman JL, Guenin E, Harris S, Bhatt V. Eichenfield LF, et al. Among authors: guenin e. Pediatr Dermatol. 2019 Mar;36(2):193-199. doi: 10.1111/pde.13744. Epub 2019 Jan 18. Pediatr Dermatol. 2019. PMID: 30656753 Free PMC article. Clinical Trial.

4

Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.

Cook-Bolden FE, Weinkle SH, Guenin E, Bhatt V. Cook-Bolden FE, et al. Among authors: guenin e. J Drugs Dermatol. 2019 Jan 1;18(1):32-38. J Drugs Dermatol. 2019. PMID: 30681791 Clinical Trial.

5

Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.

Kircik LH, Baldwin H, Lain E, Guenin E, Harris S, Bhatt V. Kircik LH, et al. Among authors: guenin e. J Drugs Dermatol. 2019 Feb 1;18(2):178-188. J Drugs Dermatol. 2019. PMID: 30811141 Clinical Trial.

6

Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups.

Harper JC, Roberts WE, Zeichner JA, Guenin E, Bhatt V, Pillai R. Harper JC, et al. Among authors: guenin e. J Dermatolog Treat. 2020 Mar;31(2):160-167. doi: 10.1080/09546634.2019.1587884. Epub 2019 Apr 2. J Dermatolog Treat. 2020. PMID: 30935257 Clinical Trial.

7

A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.

Tanghetti EA, Kircik LH, Green LJ, Guenin E, Harris S, Martin G, Pillai R. Tanghetti EA, et al. Among authors: guenin e. J Drugs Dermatol. 2019 Jun 1;18(6):542. J Drugs Dermatol. 2019. PMID: 31251546 Clinical Trial.

8

Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.

Han G, Armstrong AW, Desai SR, Guenin E. Han G, et al. Among authors: guenin e. J Drugs Dermatol. 2019 Sep 1;18(9):910-916. J Drugs Dermatol. 2019. PMID: 31524347 Clinical Trial.

9

Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.

Lain E, Day D, Harper J, Guenin E. Lain E, et al. Among authors: guenin e. J Drugs Dermatol. 2019 Nov 1;18(11):1128-1138. J Drugs Dermatol. 2019. PMID: 31741356 Clinical Trial.

10

Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.

Harper JC, Baldwin H, Stein Gold L, Guenin E. Harper JC, et al. Among authors: guenin e. J Drugs Dermatol. 2019 Nov 1;18(11):1147-1154. J Drugs Dermatol. 2019. PMID: 31741360 Clinical Trial.

11

Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.

Stein Gold L, Pariser DM, Guenin E. Stein Gold L, et al. Among authors: guenin e. J Drugs Dermatol. 2019 Dec 1;18(12):1218-1225. J Drugs Dermatol. 2019. PMID: 31860209 Clinical Trial.

12

Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.

Tanghetti EA, Werschler WP, Lain T, Guenin E, Martin G, Pillai R. Tanghetti EA, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Jan 1;19(1):70-77. doi: 10.36849/JDD.2020.3977. J Drugs Dermatol. 2020. PMID: 31985914 Clinical Trial.

13

Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.

Cook-Bolden FE, Gold MH, Guenin E. Cook-Bolden FE, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Jan 1;19(1):78-85. doi: 10.36849/JDD.2020.3979. J Drugs Dermatol. 2020. PMID: 32023013 Clinical Trial.

14

New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.

Eichenfield LF, Tanghetti EA, Guenin E, Martin G, Pillai R. Eichenfield LF, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Jun 1;19(6):602-610. doi: 10.36849/JDD.2020.10.36849/JDD.2020.4959. J Drugs Dermatol. 2020. PMID: 32574011 Clinical Trial.

15

Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.

Eichenfield LF, Elewski B, Sugarman JL, Rosen T, Vlahovic TC, Gupta AK, Pillai R, Guenin E. Eichenfield LF, et al. Among authors: guenin e. J Am Acad Dermatol. 2021 Apr;84(4):1140-1142. doi: 10.1016/j.jaad.2020.06.1004. Epub 2020 Jul 2. J Am Acad Dermatol. 2021. PMID: 32622145 Clinical Trial. No abstract available.

16

Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.

Bhatia N, Weiss JS, Sadick N, Cook-Bolden FE, Tyring SK, Guenin E, Loncaric A, Harris S. Bhatia N, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Jul 1;19(7):727-734. doi: 10.36849/JDD.2020.5125. J Drugs Dermatol. 2020. PMID: 32726105 Clinical Trial.

17

Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex.

Kircik LH, Gold LS, Beer K, Tan J, Baldwin H, Guenin E, Kang R, Varughese J. Kircik LH, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Aug 1;19(8):777-783. doi: 10.36849/JDD.2020.5249. J Drugs Dermatol. 2020. PMID: 32845584 Clinical Trial.

18

The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris.

Tyring SK, Kircik L, Pariser DM, Woolery-Lloyd HC, Harper JC, Bhatt V, Pillai R, Guenin E. Tyring SK, et al. Among authors: guenin e. Am J Clin Dermatol. 2020 Dec;21(6):891-899. doi: 10.1007/s40257-020-00559-3. Am J Clin Dermatol. 2020. PMID: 32886337 Clinical Trial.

19

Tolerability of tretinoin lotion 0.05% for moderate to severe acne vulgaris: a post hoc analysis in a black population.

Bhatia ND, Werschler WP, Cook-Bolden FE, Guenin E. Bhatia ND, et al. Among authors: guenin e. Cutis. 2020 Jul;106(1):45-50;E1. doi: 10.12788/cutis.0059. Cutis. 2020. PMID: 32915939 Clinical Trial.

20

Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.

Eichenfield LF, Elewski B, Sugarman JL, Rosen T, Vlahovic TC, Gupta AK, Stein Gold L, Pillai R, Guenin E. Eichenfield LF, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Sep 1;19(9):867-872. doi: 10.36849/JDD.2020.10.36849/JDD.2020.5401. J Drugs Dermatol. 2020. PMID: 33026753 Clinical Trial.

21

Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.

Kircik LH, Lain E, Gold M, Katz B, Baldwin H, Guenin E, Loncaric A, Pillai R. Kircik LH, et al. Among authors: guenin e. J Drugs Dermatol. 2020 Nov 1;19(11):1086-1092. doi: 10.36849/JDD.2020.5457. J Drugs Dermatol. 2020. PMID: 33196747 Clinical Trial.

22

A Split-face, Controlled Study to Assess the Compatibility of Tretinoin 0.05% Acne Lotion with Facial Foundation Makeup.

Bhatia N, Kircik LH, Shamban A, Bhatt V, Pillai R, Guenin E. Bhatia N, et al. Among authors: guenin e. J Clin Aesthet Dermatol. 2020 Oct;13(10):E53-E58. Epub 2020 Oct 1. J Clin Aesthet Dermatol. 2020. PMID: 33584959 Free PMC article.

23

Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II Post-hoc Analysis.

Baldwin HE, Green LJ, Kircik L, Guenin EP, Forest AL, Pillai R. Baldwin HE, et al. Among authors: guenin ep. J Clin Aesthet Dermatol. 2021 Apr;14(4):E53-E60. Epub 2021 Apr 1. J Clin Aesthet Dermatol. 2021. PMID: 34055190 Free PMC article.

24

Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.

Green LJ, Del Rosso JQ, Tanghetti EA, Guenin E. Green LJ, et al. Among authors: guenin e. J Drugs Dermatol. 2021 Jun 1;20(6):608-615. doi: 10.36849/JDD.2021.6070. J Drugs Dermatol. 2021. PMID: 34076400 Clinical Trial.

25

In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream.

Draelos Z, Tanghetti E, Werschler W, Kircik L, Angel A, Lagmay E, Guenin E. Draelos Z, et al. Among authors: guenin e. J Drugs Dermatol. 2022 Mar 1;21(3):250-257. doi: 10.36849/JDD.6703. J Drugs Dermatol. 2022. PMID: 35254756

26

Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.

Stein Gold L, Kircik L, Baldwin H, Callender V, Tanghetti E, Del Rosso J, Zeichner J, Cook-Bolden F, Guenin E. Stein Gold L, et al. Among authors: guenin e. J Drugs Dermatol. 2022 Jun 1;21(6):587-595. doi: 10.36849/JDD.6876. J Drugs Dermatol. 2022. PMID: 35674760 Clinical Trial.

27

Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.

Keri J, Cook-Bolden FE, Green L, Kircik LH, Baldwin H, Werschler WP, Guenin E, Pillai R, Bhatt V. Keri J, et al. Among authors: guenin e. J Dermatolog Treat. 2022 Sep;33(6):2790-2799. doi: 10.1080/09546634.2022.2071823. Epub 2022 Jul 14. J Dermatolog Treat. 2022. PMID: 35833564

28

Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream.

Draelos Z, Tanghetti E, Guenin E. Draelos Z, et al. Among authors: guenin e. J Drugs Dermatol. 2022 Aug 1;21(8):875-880. doi: 10.36849/JDD.6945. J Drugs Dermatol. 2022. PMID: 35946981 Clinical Trial.

29

Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.

Del Rosso J, Stein Gold L, Tyring S, Zeichner J, Callender V, Draelos Z, Werschler W, Cook-Bolden F, Guenin E. Del Rosso J, et al. Among authors: guenin e. J Drugs Dermatol. 2022 Oct 1;21(10):1061-1069. doi: 10.36849/JDD.6834. J Drugs Dermatol. 2022. PMID: 36219057 Clinical Trial.

30

Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.

Tanghetti EA, Zeichner JA, Gold M, Sadick N, Cook-Bolden FE, Kircik LH, Stein Gold L, Weiss J, Tyring SK, Del Rosso JQ, Guenin E. Tanghetti EA, et al. Among authors: guenin e. J Dermatolog Treat. 2023 Dec;34(1):2147391. doi: 10.1080/09546634.2022.2147391. J Dermatolog Treat. 2023. PMID: 36382987 Free article. Clinical Trial.

31

Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.

Harper JC, Kircik LH, Gold M, Hebert AA, Sugarman JL, Green L, Gold LS, Baldwin H, Guenin E, DelRosso JQ. Harper JC, et al. Among authors: guenin e. J Drugs Dermatol. 2024 Mar 1;23(3):125-131. doi: 10.36849/jdd.7907. J Drugs Dermatol. 2024. PMID: 38443130 Clinical Trial.

32

Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.

Kircik LH, Green L, Guenin E, Khalid W, Alexander B. Kircik LH, et al. Among authors: guenin e. J Dermatolog Treat. 2022 Jun;33(4):2241-2249. doi: 10.1080/09546634.2021.1944969. Epub 2021 Aug 30. J Dermatolog Treat. 2022. PMID: 34459694 Clinical Trial.

33

Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-severe Acne Vulgaris in a Preadolescent and Adolescent Population.

St Surin-Lord S, Schlesinger TE, Guenin E. St Surin-Lord S, et al. Among authors: guenin e. J Clin Aesthet Dermatol. 2019 Sep;12(9):E57-E61. Epub 2019 Sep 1. J Clin Aesthet Dermatol. 2019. PMID: 31641421 Free PMC article.

34

50 Years of Topical Retinoids for Acne: Evolution of Treatment.

Baldwin H, Webster G, Stein Gold L, Callender V, Cook-Bolden FE, Guenin E. Baldwin H, et al. Among authors: guenin e. Am J Clin Dermatol. 2021 May;22(3):315-327. doi: 10.1007/s40257-021-00594-8. Am J Clin Dermatol. 2021. PMID: 33871811 Review.

35

Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.

Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, Stein Gold L, Guenin E. Callender VD, et al. Among authors: guenin e. Am J Clin Dermatol. 2022 Jan;23(1):69-81. doi: 10.1007/s40257-021-00643-2. Epub 2021 Nov 9. Am J Clin Dermatol. 2022. PMID: 34751927 Free PMC article. Review.

36

One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis.

Gupta AK, Venkataraman M, Anbalagan N, Guenin EP. Gupta AK, et al. Int J Dermatol. 2021 Oct;60(10):1296-1302. doi: 10.1111/ijd.15739. Epub 2021 Jul 3. Int J Dermatol. 2021. PMID: 34216026 Review.

37

JUBLIA (Efinaconazole 10% Solution) in the Treatment of Pediatric Onychomycosis.

Gupta AK, Venkataraman M, Abramovits W, Guenin EP. Gupta AK, et al. Skinmed. 2021 Jun 1;19(3):206-210. eCollection 2021. Skinmed. 2021. PMID: 34303391

38

Guaifenesin Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years.

Thompson GA, Solomon G, Albrecht HH, Reitberg DP, Guenin E. Thompson GA, et al. Among authors: guenin e. J Clin Pharmacol. 2016 Jul;56(7):894-901. doi: 10.1002/jcph.682. Epub 2016 Jan 24. J Clin Pharmacol. 2016. PMID: 26632082 Free PMC article.

39

Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.

Guenin E, Armogida M, Riff D. Guenin E, et al. Clin Drug Investig. 2014 Sep;34(9):609-16. doi: 10.1007/s40261-014-0210-5. Clin Drug Investig. 2014. PMID: 25027615 Clinical Trial.

40

Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief in Support of a Wait-and-See Approach for the Treatment of Acute Upper Respiratory Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Study.

Septimus EJ, Albrecht HH, Solomon G, Shea T, Guenin EP. Septimus EJ, et al. Curr Ther Res Clin Exp. 2017 Apr 28;84:54-61. doi: 10.1016/j.curtheres.2017.04.004. eCollection 2017. Curr Ther Res Clin Exp. 2017. PMID: 28761581 Free PMC article.

41

Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections.

Albrecht HH, Dicpinigaitis PV, Guenin EP. Albrecht HH, et al. Multidiscip Respir Med. 2017 Dec 11;12:31. doi: 10.1186/s40248-017-0113-4. eCollection 2017. Multidiscip Respir Med. 2017. PMID: 29238574 Free PMC article. Review.

42

Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents.

Gupta AK, Elewski B, Joseph WS, Lipner SR, Daniel CR, Tosti A, Guenin E, Ghannoum M. Gupta AK, et al. Among authors: guenin e. Mycoses. 2024 Jan;67(1):e13683. doi: 10.1111/myc.13683. Mycoses. 2024. PMID: 38214375 Review.

43

Fluid Mechanics of Droplet Spreading of Chitosan/PVA-Based Spray Coating Solution on Banana Peels with Different Wettability.

Wardhono EY, Kanani N, Pinem MP, Sukamto D, Meliana Y, Saleh K, Guénin E. Wardhono EY, et al. Among authors: guenin e. Polymers (Basel). 2023 Oct 31;15(21):4277. doi: 10.3390/polym15214277. Polymers (Basel). 2023. PMID: 37959957 Free PMC article.

44

Pd nanoparticles embedded in nanolignin (Pd@LNP) as a water dispersible catalytic nanoreactor for Cr(VI), 4-nitrophenol reduction and CC coupling reactions.

Zhang Z, Lefebvre C, Somerville SV, Tilley RD, Guénin E, Terrasson V. Zhang Z, et al. Among authors: guenin e. Int J Biol Macromol. 2024 Jan;254(Pt 2):127695. doi: 10.1016/j.ijbiomac.2023.127695. Epub 2023 Oct 31. Int J Biol Macromol. 2024. PMID: 37913877

45

Microwave-Assisted Synthesis of Pd Nanoparticles into Wood Block (Pd@wood) as Efficient Catalyst for 4-Nitrophenol and Cr(VI) Reduction.

Zhang Z, Besserer A, Rose C, Brosse N, Terrasson V, Guénin E. Zhang Z, et al. Among authors: guenin e. Nanomaterials (Basel). 2023 Sep 4;13(17):2491. doi: 10.3390/nano13172491. Nanomaterials (Basel). 2023. PMID: 37686999 Free PMC article.

46

Fucoidan-coated coils improve healing in a rabbit elastase aneurysm model.

Szatmáry Z, Bardet SM, Mounier J, Janot K, Cortese J, Perrin ML, Couquet C, Deniau G, Hauquier F, Migneret R, Guenin E, Maire M, Michel JB, Forestier G, Le Flahec A, Leger-Bretou C, Mounayer C, Chaubet F, Rouchaud A. Szatmáry Z, et al. Among authors: guenin e. J Neurointerv Surg. 2023 Jul 25:jnis-2023-020596. doi: 10.1136/jnis-2023-020596. Online ahead of print. J Neurointerv Surg. 2023. PMID: 37491380

47

Purification of Natural Pigments Violacein and Deoxyviolacein Produced by Fermentation Using Yarrowia lipolytica.

Nemer G, Louka N, Rabiller Blandin P, Maroun RG, Vorobiev E, Rossignol T, Nicaud JM, Guénin E, Koubaa M. Nemer G, et al. Among authors: guenin e. Molecules. 2023 May 24;28(11):4292. doi: 10.3390/molecules28114292. Molecules. 2023. PMID: 37298767 Free PMC article.

48

A continuous flow mode with a scalable tubular reactor for the green preparation of stable alkali lignin nanoparticles assisted by ultrasound.

Assaf I, Zhang Z, Otaola F, Leturia M, Luart D, Terrasson V, Guénin E. Assaf I, et al. Among authors: guenin e. Int J Biol Macromol. 2023 Jul 15;243:125106. doi: 10.1016/j.ijbiomac.2023.125106. Epub 2023 May 29. Int J Biol Macromol. 2023. PMID: 37257546

49

Modification of Physio-Mechanical Properties of Chitosan-Based Films via Physical Treatment Approach.

Wardhono EY, Pinem MP, Susilo S, Siom BJ, Sudrajad A, Pramono A, Meliana Y, Guénin E. Wardhono EY, et al. Among authors: guenin e. Polymers (Basel). 2022 Nov 30;14(23):5216. doi: 10.3390/polym14235216. Polymers (Basel). 2022. PMID: 36501610 Free PMC article.

50

Additive manufacturing of microstructured reactors for organometallic catalytic reactions.

Otaola F, Mottelet S, Guénin E, Luart D, Leturia M. Otaola F, et al. Among authors: guenin e. Lab Chip. 2023 Feb 14;23(4):702-713. doi: 10.1039/d2lc00816e. Lab Chip. 2023. PMID: 36412241

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page